Thermo Fisher Scientific SARS-CoV-2 RBD Neutralizing Monoclonal Antibody (OTI1C2), TrueMAB

Applications

Tested Dilution

Publications

ELISA (ELISA)

1:5,000-1:10,000

-

Neutralization (Neu)

Assay-dependent

-

Product Specifications

Species Reactivity

Virus

Host/Isotype

Mouse / IgG1

Class

Monoclonal

Type

Antibody

Clone

OTI1C2

Immunogen

Recombinant fusion protein of SARS-CoV-2 Spike RBD protein and virion surface domain of membrane protein (M-protein) produced in HEK293

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Lyophilized

Concentration

See Label

Purification

Protein A/G

Storage buffer

PBS, pH 7.3, with 8% trehalose

Contains

no preservative

Storage conditions

-20° C, Avoid Freeze/Thaw Cycles

Shipping conditions

Wet ice

Target Information

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold symptoms to severe effects including death and respiratory distress. The CoV Spike (S) protein plays the most important roles in viral attachment, fusion and entry, and serves as a target for development of antibodies, entry inhibitors and vaccines. Of note is the Spike protein receptor-binding domain (RBD, S-RBD) in SARS-CoV-2 Spike protein which binds strongly to human and bat angiotensin-converting enzyme 2 (ACE2) receptors. SARS-CoV-2 RBD exhibits significantly higher binding affinity to ACE2 receptor than SARS-CoV RBD in comparison. S1 contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on target cells.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.